New treatment approach for relapsed childhood leukemia using arsenic compounds

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the efficacy of arsenic trioxide (ATO) and a traditional Chinese medicine formula, Realgar Indigo naturalis, in treating children with relapsed acute lymphoblastic leukemia (ALL). The study aims to improve the minimal residual disease (MRD) negative rate after induction therapy by combining these treatments with conventional chemotherapy. It employs a double-blind randomized controlled design to ensure unbiased results and focuses on children classified as intermediate or high risk. The trial is based on previous findings that suggest ATO can inhibit leukemia cell growth and induce cell death.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* B or T cell type;
* the first recurrence;
* the risk stratification was medium or high risk.

Exclusion Criteria:

* mature B cell leukemia;
* acute mixed phenotype leukemia;
* patients with positive BCR/ABL fusion gene;
* the second tumor
* definite CML blast crisis;
* ALL with Down's syndrome.

Where it's running

• Sun Yat-sen Memorial Hospital, Sun Yat-sen University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Pei J Fang, Doctoral
• Email: jpfang2005@163.com
• Phone: 13682290830

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Oral arsenic trioxide plus vitamin C with low-intensity therapy for TP53-mutated AML/MDS/CMML

  This trial will test whether taking oral arsenic trioxide with vitamin C plus a low-intensity drug (a hypomethylating agent, with or without venetoclax) helps adults with TP53-mutated AML, MDS, or CMML who are newly diagnosed or have relapsed/refractory disease.

  Recruiting Phase 2 The University of Hong Kong · Hong Kong · NCT06778187

• New treatment recommendations for children with Acute Lymphoblastic Leukemia

  This study is testing new treatment guidelines for children with Acute Lymphoblastic Leukemia to see if they can help more kids go into remission and stay cancer-free.

  Recruiting at 3 sites French Africa Pediatric Oncology Group · Abidjan and 2 other locations · NCT04794296

• One-Finger Technique to identify the left upper ureter during para-aortic lymphadenectomy

  This study tests a new surgical method to help surgeons find the left upper ureter during open para-aortic lymphadenectomy in women with gynecologic cancers.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07895212

• MRG003 added to ongoing treatment after progression in EGFR-positive advanced thyroid cancer

  In this study, researchers test whether adding MRG003 to a patient’s current thyroid cancer treatment can shrink tumors for those whose cancer initially responded but later progressed.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07874321

• Reducing Endotoxin Burden in Septic Shock Patients on CRRT with the oXiris Filter

  This trial tests whether using the oXiris hemofilter during continuous kidney replacement helps lower endotoxin levels in adults with septic shock who need CRRT.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07807410

• First-line combo therapy with anlotinib, benmelstobart, and HAIC for unresectable HCC

  This study tests whether adding benmelstobart and hepatic arterial infusion chemotherapy to anlotinib can help people with unresectable hepatocellular carcinoma respond to treatment as a first line.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07806292

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.